10:48 AM EST - Resverlogix Corp. : Today announced the publication of an article entitled “Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators” in the journal Biomedicine & Pharmacotherapy. The article uncovers a clear mechanism for the improved safety, and reduced off-target effects, seen with BD2-selective BET inhibitors in comparison with non-selective BET inhibitors. Resverlogix Corp.
shares T.RVX are trading u0p $0.04 at $0.26.
